Comparing Organigram Global (NASDAQ:OGI) & iRadimed (NASDAQ:IRMD)

Organigram Global (NASDAQ:OGI) and iRadimed (NASDAQ:IRMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Institutional & Insider Ownership

34.6% of Organigram Global shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 0.1% of Organigram Global shares are owned by company insiders. Comparatively, 34.6% of iRadimed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Organigram Global and iRadimed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organigram Global	28.14%	-13.39%	-8.67%
iRadimed	26.70%	23.45%	20.36%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Organigram Global and iRadimed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	0	1	2	0	2.67
iRadimed	0	3	2	1	2.67

iRadimed has a consensus price target of $120.00, suggesting a potential upside of 33.85%. Given iRadimed’s higher probable upside, analysts plainly believe iRadimed is more favorable than Organigram Global.

Earnings & Valuation

This table compares Organigram Global and iRadimed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram Global	$185.07 million	0.70	-$17.70 million	$0.46	2.00
iRadimed	$83.81 million	13.68	$22.48 million	$1.79	50.08

iRadimed has lower revenue, but higher earnings than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Organigram Global has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, iRadimed has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Summary

iRadimed beats Organigram Global on 9 of the 12 factors compared between the two stocks.

About Organigram Global

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.